You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Vaccine-enhanced DLI to prevent cancer recurrence after stem cell transplantation

    SBC: CERUS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Delayed reconstitution of antigen-specific immunity following allogeneic hematopoietic stem cell transplantation (HSCT) predisposes patients to opportunistic infections and tumor recurrence. To address these problems, we are developing a vaccination methodology using a non-replicating but highly immunogenic Listeria monocytogenes (Lm) vector. When an Lm vaccine ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Cell-based screening of combinatorial siRNA libraries

    SBC: CYNTELLECT, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): RNA interference (RNAi) is a specific post-transcriptional gene silencing pathway mediated by intracellular dsRNAs of 21-23 bp in length known as small interfering RNA (siRNA). Since the recent discovery of effective siRNA-mediated gene silencing in mammalian cells, there has been significant validation and enormous interest in the approach from both academic a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Evolutionary Approaches for synthetic Library Design

    SBC: DNA Twopointo Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Directed evolution has been widely employed to enhance protein structural stability and activity, expand functionality and alter specificity. We propose a novel approach for generating libraries of variant genes that takes advantage of the evolutionary history of a gene family by generating a combinatorial library incorporating amino acid replacements inferred ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. LabOS Closed-loop, Protocol-driven, Data Acquisition & Experiment Control

    SBC: Eidactics            Topic: N/A

    DESCRIPTION (provided by applicant): Significant Aims: Biomedical research, human performance and other laboratories that work with living subjects and perform complex experiments unanticipated by software "solution" providers, must expend significant resources creating & maintaining data acquisition and control (DAQ&C) systems that are seldom useful in other labs because of their complexity or po ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Cloned pigs for Xenotransplantation

    SBC: EVERGEN BIOTECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of the proposed research is to develop methods to create immune protected universal donor cloned transgenic pigs for xenotransplantation. According to the United Network of Organ Sharing (UNOS) more than 30,000 organ transplants are performed in the US alone, yet greater than 95,000 people are currently on the waiting list to receive donors organs f ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Model-Driven Strain Engineering for Isoprenoid Drug Production

    SBC: GENOMATICA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Engineering microbial strains with superior production capabilities is one of the most challenging and intriguing endeavors in bioprocess development. However, due to the lack of rational and systematic approaches, the timelines and cost for strain development can be large and at times prohibitive for many products. In this STTR, we will utilize an integrated c ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Newborn Screening for Sex Chromosome Disorders

    SBC: JS GENETICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Turner syndrome (TS) is the most common genetic problem effecting women, with an incidence of 1 in 1,500 to 2,000 live female births and occurs when an entire, or portions of an X-chromosome is deleted. Phenotypic features include primary hypogonadism, renal abnormalities, and profound short stature. Yet, with growth hormone therapy, acceptable adult stature c ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Lipid/DNA/Antigen Complexes for Influenza A Viral Vaccination

    SBC: JUVARIS BIOTHERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza A (fluA) infection causes annual substantial morbidity and mortality worldwide, particularly for infants, the elderly, and the immuncompromised. FluA mainly replicates in the respiratory tract, with virulent strains also disseminating to other tissues, such as the central nervous system. A growing concern is the recent spread of virulent avian influen ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. A Genetic Test for Drug-Induced Dyskinesia Risk

    SBC: KOVOGEN            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this project is to develop a genetic test, involving the protein, RGS9, to identify patients that are at risk for developing tardive dyskinesia (TD) or L-DOPA induced dyskinesia (LID). Antipsychotic drugs have revolutionized the treatment of schizophrenia and psychotic disorders but a debilitating side-effect of "typical" antipsychotics is TD, ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government